Browse
Submit Data
Databases
API
Help

Dataset Information

2 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

ABSTRACT: The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.

DISEASE(S): Colorectal Cancer (crc),Lung Cancer,Pancreatic Cancer,Breast Cancer,Solid Tumors

PROVIDER: 2229234 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Real-time quantitative PCR analysis of mice kidney after administration of Lu-177-octreotate, Lu-177-octreotate + A1M and A1M

Project description:This work aimed to examine the regulation of apoptosis-related genes in kidney cortex and kindey medulla one and seven days after administration of 177Lu-octreotate with and without A1M and of A1M alone. C57BL/6N mice were injected with either 177Lu-octreotate + PBS, A1M + PBS or 177Lu-octreotate + A1M. Also, a control group was sham-treated with saline. Half of the animals in each treatment and control group were terminated by cardiac puncture one-day post-injection (1 dpi), and the remaining animals were terminated at 7dpi. Kidneys were dissected at the time of termination, snap-frozen in liquid nitrogen and stored at -80°C.

2024-04-01 | GSE200619 | GEO

BMS_IM101042_Baseline_WB_study

Project description:The goal of this study is to define the molecular signatures of SLE patients at baseline in BMS IM101042 trial. IM101042 (NCT00119678) is a phase IIb, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept vs placebo on a background of oral glucocorticosteroids in the treatment of subjects with systemic lupus erythematosus and the prevention of subsequent lupus flares, sponsored by Bristol-Myers Squibb.

2018-02-07 | GSE110174 | GEO

RT-qPCR analysis of apoptosis related genes in patient-derived xenografts of small intestine neuroendocrine tumors in Balb/c NM after administration of Lu-177-octreotate, Lu-177-octreotate + A1M and A1M

Project description:This work aimed to examine the regulation of apoptosis-related genes in GOT1 tumors one and seven days after administration of 177Lu-octreotate with and without A1M and of A1M alone. At study start, 22 adult female Balb/c GOT1 tumor-bearing mice were divided into four groups of six animals that received 30 MBq 177Lu-octreotate or 5 mg/kg A1M, or co-treatment with both 177Lu-octreotate and A1M by i.v. injection. Also, a control group was sham-treated with saline. Half of the animals in each treatment and control group were terminated by cardiac puncture one-day post-injection (1 dpi), and the remaining animals were terminated at 7dpi. Tumor tissues were dissected at the time of termination, snap-frozen in liquid nitrogen and stored at -80°C.

2023-04-25 | GSE200449 | GEO

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Project description:The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.

| 2301010 | ecrin-mdr-crc

caArray_willm-00144: Gene Expression Profiling for Molecular Classification and Outcome Prediction in Infant Leukemia Reveals Novel Biologic Clusters and Pathways for Treatment Failure

Project description:126 infant leukemia cases registered to NCI-sponsored Infant Oncology Group/Children's Oncology Group treatment trials were studied using oligonucleotide microarrays containing 12,625 probe sets (Affymetrix U95Av2 platform)

2016-12-23 | GSE92781 | GEO

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Project description:This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.

| 2106666 | ecrin-mdr-crc

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Project description: Not available

| S-EPMC5647109 | biostudies-literature

caArray_smith-00014: Expression profiling of acute lymphoblastic leukemia

Project description:Target Project: Expression profiling of acute lymphoblastic leukemia samples using U133plus2 affymetrix arrays. The study was sponsored by the national cancer institute with a goal to catalog genomic changes in ALL pre and post standard therapies.

2016-06-21 | GSE83536 | GEO

Ontology-based federated data access to human studies information.

Project description: Not available

| S-EPMC3540523 | biostudies-literature

The Association of Patient Factors, Digital Access, and Online Behavior on Sustained Patient Portal Use: A Prospective Cohort of Enrolled Users.

Project description: Not available

| S-EPMC5663951 | biostudies-literature